

# Inpatient Management of Viral Croup



**Inclusion Criteria §**

- Healthy child 6 months to 6 years of age with a presentation consistent with a primary diagnosis of croup

**Exclusion Criteria §**

- Toxic appearance
- Chronic lung disease/bronchopulmonary dysplasia or other serious lung disease
- Neuromuscular disease or other complex co-morbid conditions complicating care
- History of chronic/recurrent aspiration
- Recent airway instrumentation or intubation
- Known upper airway abnormality
  - Laryngomalacia
  - Tracheomalacia
  - History of vascular ring
  - History of TEF
  - Subglottic stenosis
  - Vocal cord paralysis

Previously healthy child with diagnosis of Croup  
age 6 months to 6 years §‡  
(Refer to Table 1 on Page 2)

**Initial assessment**

**Focused history:**

- Age
- Duration of symptoms
- History of prior episodes
- Ability to feed/drink
- History of drooling

**Focused physical exam:**

- General appearance
- Respiratory rate
- O2 saturation
- Work of breathing (retractions, flaring, etc)
- Presence of stridor (at rest or with activity)

**Admission Criteria ‡**

- Continued stridor at rest and any signs of moderate to severe respiratory distress
- Receiving 2 or more doses of racemic epinephrine in the ED or outpatient setting
- Supplemental oxygen requirement
- Dehydration and unable to maintain oral hydration
- Not otherwise meeting ED Discharge criteria

**Mild Croup**

- No stridor at rest (can have stridor with activity/agitation)
- No or mild WOB

**Moderate Croup**

- Stridor at rest
- Moderate work of breathing with tachypnea and retractions
- Difficulty with feeding/talking
- NO mental status changes

**Severe Croup**

- Stridor at rest
- Severe work of breathing with retractions, respiratory fatigue, self-positioning (tripoding, neck extension)
- Inability to talk or feed
- +/- mental status changes with decreased consciousness or agitation

- Give systemic corticosteroids\* if not previously given (Refer to Tables 3 and 4 on page 2)
- Supportive care for viral process (Refer to Table 2 on page 2)

- Give racemic epinephrine (Refer to Tables 3 and 4 on page 2)
- Give systemic corticosteroids\* if not previously given
- Supportive care for viral process (Refer to Table 2 on page 2)

Re-assess q1h x 2 (RN, RT)

\* Dexamethasone injection for oral use

Stridor and increased work of breathing persists and recurs?

**NO**

Symptoms improve

Repeat clinical assessment every 1-4 hours depending on disease severity

**YES**

- MD evaluation at the bedside
- Consider repeat dose of racemic epinephrine q2h as needed for symptoms of moderate/severe

Re-assess q1h x 2 (RN, RT) after each additional racemic epinephrine

If symptoms persist/recur within 2 hours from last racemic epinephrine or signs of clinical deterioration (Refer to Table 5 on page 2):

- Consider an additional racemic epinephrine and/or parenteral steroids
- Call RRT for PICU evaluation (or transfer to CCMC)
- Consider alternative diagnosis (Refer to Table 1 on page 2)

Discontinue pathway

**Discharge Criteria**

- No stridor or mild stridor
- Received steroids
- No or minimal respiratory distress/retractions
- 6-8 hours from last racemic epinephrine
- Off supplemental O2 for 6-8 hours with normal O2 saturations
- Able to tolerate PO
- No social barriers to continued care on discharge
- Appropriate PMD follow up



Table 1	Table 2	Table 3	Table 4	Table 5
<p><b><u>Consider alternative diagnosis:</u></b></p> <ul style="list-style-type: none"> <li>• Age &lt; 6 months or &gt; 6 years</li> <li>• Poor response to treatment</li> <li>• History of choking with acute onset of cough (consider foreign body)</li> <li>• Prolonged duration of stridor (&gt; 4 days) or of cough (&gt; 10 days)</li> <li>• Recent intubation (within the last 6 months) or history of intubation</li> <li>• Recurrence of croup symptoms (2<sup>nd</sup> episode within 30 days or &gt; 3 or 12 months)</li> <li>• Hypoxia/cyanosis</li> <li>• Multiple cutaneous hemangiomas present</li> <li>• Asymmetry of the respiratory exam or expiratory wheeze</li> <li>• Drooling, difficulty swallowing</li> <li>• Toxic-appearance, rapid decompensation</li> </ul>	<p><b><u>Supportive care:</u></b></p> <ul style="list-style-type: none"> <li>• Avoid painful procedures and maintain a calm atmosphere</li> <li>• Antipyretics as needed</li> <li>• Maintain hydration</li> <li>• Placement on isolation precautions</li> <li>• Supplemental O2 as needed for hypoxia (Refer to Table 1)</li> </ul>	<p><b><u>Treatment considerations:</u></b></p> <ul style="list-style-type: none"> <li>• Mild Croup: dexamethasone* 0.3 mG/kG (max dose 10 mG)</li> <li>• Moderate/severe Croup: dexamethasone* 0.6 mG/kG (max dose 10 mG)</li> <li>• Can consider 0.6 mG/kG parenterally for severe croup</li> <li>• 2 mG budesonide should be considered if PO medications are not tolerated, IV access is unobtainable and the severity of symptoms makes IM dexamethasone* not optimal due to its delayed onset</li> <li>• Racemic epinephrine 2.25% inhalation solution (0.5 mL in 3 mL saline)</li> <li>• Supportive care of viral illness (Refer to Table 2)</li> </ul>	<p><b><u>Therapies not routinely recommended:</u></b></p> <ul style="list-style-type: none"> <li>• Testing with respiratory viral panel</li> <li>• Radiographs</li> <li>• Cool mist</li> <li>• Repeat dexamethasone dosing</li> <li>• Continuous pulse oximetry</li> </ul>	<p><b><u>Signs of impending respiratory failure:</u></b></p> <ul style="list-style-type: none"> <li>• Stridor may be present or absent (due to diminished air flow)</li> <li>• Severe work of breathing</li> <li>• Bradypnea or poor respiratory effort</li> <li>• Cyanosis/hypoxemia despite supplemental oxygen</li> <li>• Hypercarbia</li> <li>• Listlessness or decreased consciousness</li> </ul> <p style="text-align: right;">PCEC Approval Date: 2/12/2020</p>